156 related articles for article (PubMed ID: 10754704)
1. PDA comments: PIC draft recommendations on the inspection of isolator technology. Parenteral Drug Association.
PDA J Pharm Sci Technol; 1999; 53(3):141-7. PubMed ID: 10754704
[No Abstract] [Full Text] [Related]
2. Good validation practices: FDA issues.
Levchuk JW
PDA J Pharm Sci Technol; 1994; 48(5):221-3. PubMed ID: 8000894
[No Abstract] [Full Text] [Related]
3. Aseptic process monitoring--a better strategy. Validation Group, Inc.
Wilson JD
PDA J Pharm Sci Technol; 1999; 53(3):111-4. PubMed ID: 10754699
[No Abstract] [Full Text] [Related]
4. The influence of clean room design on product contamination.
Whyte W
J Parenter Sci Technol; 1984; 38(3):103-8. PubMed ID: 6747777
[No Abstract] [Full Text] [Related]
5. PDA presentation at FDA Open Conference on Sterile Drug Manufacturing. Parenteral Drug Association.
J Pharm Sci Technol; 1994; 48(1):4-6. PubMed ID: 8004417
[No Abstract] [Full Text] [Related]
6. Need for specific-gravity values in adopting gravimetric measurement in sterile compounding.
Roberts PA; Valgus JM; Willoughby IR; Amerine LB
Am J Health Syst Pharm; 2017 Jun; 74(12):871-872. PubMed ID: 28596223
[No Abstract] [Full Text] [Related]
7. Design control and validation of a facility for sterile clinical trial preparations.
Staines L
J Parenter Sci Technol; 1984; 38(3):109-14. PubMed ID: 6747778
[No Abstract] [Full Text] [Related]
8. Opportunities and obstacles in the implementation of barrier technology.
Agalloco J
PDA J Pharm Sci Technol; 1995; 49(5):244-8. PubMed ID: 7489199
[TBL] [Abstract][Full Text] [Related]
9. Environmental microbial challenges to an aseptic Blow-Fill-Seal process--a practical study.
Jones DJ; Topping P; Sharp J
PDA J Pharm Sci Technol; 1995; 49(5):226-34. PubMed ID: 7489196
[TBL] [Abstract][Full Text] [Related]
10. Rapid/automated ID methods survey. PDA Microbial ID Task Force. Parenteral Drug Association.
J Parenter Sci Technol; 1990; 44(4):216-22. PubMed ID: 2213430
[No Abstract] [Full Text] [Related]
11. [Validation of procedure for sterile manufacturing. Simulated distribution in containers, in a sterile area].
Arecco D; Carazzone M; Fava M
Boll Chim Farm; 1982 Oct; 121(10):493-502. PubMed ID: 7165749
[No Abstract] [Full Text] [Related]
12. Some further comments on aseptic processing guidance, or the fool on the hill: Parenteral Drug Association.
Agalloco J
PDA J Pharm Sci Technol; 2003; 57(5):324-30. PubMed ID: 14677624
[No Abstract] [Full Text] [Related]
13. PDA comments: PIC-S active pharmaceutical ingredients. Parenteral Drug Association.
PDA J Pharm Sci Technol; 1998; 52(5):234-5. PubMed ID: 9846072
[No Abstract] [Full Text] [Related]
14. Sterilizing filtration of liquids. Technical report no. 26. Parenteral Drug Association.
PDA J Pharm Sci Technol; 1998; 52 Suppl 1():1-31. PubMed ID: 9693385
[No Abstract] [Full Text] [Related]
15. Investigational trends: clean room environmental monitoring.
Tetzlaff RF
J Parenter Sci Technol; 1992; 46(6):206-14. PubMed ID: 1474432
[TBL] [Abstract][Full Text] [Related]
16. FDA's aseptic processing: proposed regulation.
Barr DB
J Parenter Sci Technol; 1993; 47(2):57-9. PubMed ID: 8515345
[No Abstract] [Full Text] [Related]
17. PDA comments on draft guidance for industry on changes to an approved NDA or ANDA. Parenteral Drug Association.
PDA J Pharm Sci Technol; 1999; 53(5):264-72. PubMed ID: 10754723
[No Abstract] [Full Text] [Related]
18. PDA comments: SUPAC-IR, ICH Q1C, FDA draft guideline. Parenteral Drug Association.
PDA J Pharm Sci Technol; 1995; 49(4):152-6. PubMed ID: 7552232
[TBL] [Abstract][Full Text] [Related]
19. Prolonged shutdown of an isolator because of false-positive sterility tests.
Langouet AM; Marr A; Kountny E; Etienne F
Am J Health Syst Pharm; 2001 May; 58(10):914-5. PubMed ID: 11381497
[No Abstract] [Full Text] [Related]
20. Report on survey of current industry gowning practices. PDA Gowning Task Force. Parenteral Drug Association.
J Parenter Sci Technol; 1990; 44(4):223-7. PubMed ID: 2213431
[No Abstract] [Full Text] [Related]
[Next] [New Search]
